Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Author:
Anthony J. Olszanski
Search for other papers by Anthony J. Olszanski in
Current site
Google Scholar
PubMed Close
 MD, RPh
Volume/Issue:
Volume 17: Issue 5.5
Online Publication Date:
May 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5019
Restricted access

According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations.

Correspondence: Anthony J. Olszanski, MD, RPh, Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Email: anthony.olszanski@fccc.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199–6206.

  • 3.

    Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370:599–609.

  • 4.

    Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376:2211–2222.

  • 5.

    Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681–1696.

  • 6.

    Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483–6488.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma [published online October 22, 2018]. J Clin Oncol, doi: 10.1200/JCO.18.01219

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522–530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824–1835.

Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2019
Online Publication Date:
May 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1337 635 17
PDF Downloads 336 58 2
EPUB Downloads 0 0 0